DOCSLIB.ORG

Searchable Word Index for the 11Th Edition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Index 2319 Index A Acnisal 1921 Acomplia 1891 A2 234 aconite 34 AA-3 1014 aconitine 34 AAtack 2096 acrivastine 36 AAtrex 183 acrodynia 1297, 2086 abacavir 1 acrolein 37, 567 abamectin 2, 1135 acrylamide 38 Abba 2 acrylonitrile 40 AB-CHMINACA 2008 actein 619 ABDF 284 Actidex 631 Abelcet 127 Actifed 2193 Abilify 159 actinomycin D 41 abiraterone acetate 3 Actiq 883 Abitat 159 Actimax 1471 abobotulinumtoxinA 268 Actol 1527 abortifacients 344, 1436, 1449, 1648 Actonel 1892 AB-PINACA 2008 Actos 1733 Abraxane 1617 Actril 1108 abrin 4 Acular 1148 absinthe 2097 Acupan 1503 Abstral 883 Acuphase 2303 acamprosate 5 Acuvel 180 Acapodene 2143 acyclovir 42, 2214 acarbose 6 Adalat 1525 acaricides 111, 430, 2061 adalimumab 44 Acarin 663 Adalin 370 Accolate 2277 Adapin 745 Accupril 1853 Adartrel 1904 Accuprin 1853 Adasept 2175 Accuretic 1853 ADB-FUBINACA 2008 Accutane 1127 ADB-PINACA 2008 Accutrim 1707 Adcirca 2017 Acebron 9 Adco-Linctopent 280, 1580 acebutolol 7 Adderall 124 acecainide 1787 Addyi 898 aceclofenac 8 Adecut 612 Acecor 7 adefovir dipivoxil 45 ACE inhibitors 213, 350, 612, 952, 1205, 1223, 1460, 1669, ademine 2162 1853, 1865, 2035, 2151, 2291 Adempas 1892 acenocoumarol 9 Adenocard 46 Aceon 1669 adenosine 46, 666 acephate 11 ADHD drugs (see attention deficit disorder drugs) acepromazine 12 Adiazine 1989 Acetadote 24 Adion 137 acetaldehyde 13, 338, 819, 825, 1309, 1543, 1628 Adipex 1700 acetamide 698 Adizem 685 acetaminophen 15, 142, 1676, 1679 adrafinil 47, 1459 acetamiprid 18 adrenaline 789 acetanilide 142 Adriacin 747 acetazolamide 19 Adriamycin 747 acetic acid 818, 833 adulterants 256, 1173, 1268, 1856, 1946, 1947 acetone 20, 26, 825, 1122, 1803 Advagraf 2015 acetonitrile 22 Advair 935, 1922 acetophenetidin 1676 Advancor 1519 acetylcarnitine 23 Advantage 1086 6-acetylcodeine 1032 advantame 48 acetylcysteine 24 Advicor 1224, 1511 acetylene 25 Advil 1073 acetylfentanyl 26 Aeris 2087 acetylmethadol 27 Aerobec 209 N-acetylprocainamide 1787 AeroBid 907 acetylpromazine 12 Aerolate 2081 acetylsalicylic acid 29 aerosol propellants (see propellants) Achromycin 2060 afatinib 48 Aciforin 946 Afinitor 859 Acinal 1485 aflatoxin B1 49 Acipen V 1647 Afos 1258 Aciphex 1859 Agelan 1094 acitretin 31 Agenerase 130 ackee 1068 Agent Orange 654, 713, 2171 aclidinium bromide 33 Aggrenox 722 Aclovir 42 Agilect 1869 acne drugs 576, 1127, 1921, 2159 2320 Index Agit 684 alogliptin 75 agomelatine 51 alosetron 75 Agrastat 2117 Aloxi 1621 Agritox 1367 Alpha Brain 2249 AH-7921 53 Alphagan 270 Aimpart 1904 Alphakil 418 Airbron 24 alpha-methyldopa 1371 Airtal 8 alpha-methylfentanyl 1393 Airum 880 alpha-methyltryptamine 1413 ajmaline 53 alphaprodine 76 Akatinol 1275 alprazolam 77 akee 1068 alprenolol 80 Akineton 251 alprostadil 81 Akynzeo 1509, 1621 Altace 1865 alachlor 55 Altoprev 1224 Alavert 1217 aluminum 83 albendazole 56 aluminum phosphide 1720 albiglutide 57 Alupent 1580 Albistat 1431 Alurate 152 albuterol 58 Aluvia 1214 alcohol 818 Alventa 2231 alcohol aversion therapy agents 145, 338, 728 alverine 85 alcuronium 60 Alvesco 471 Aldactazide 1968 alvimopan 83 Aldactide 1968 Alzheimer's drugs (see also nootropic agents) 23, 488, 536, Aldactone 1968 737, 967, 1046, 1078, 1275, 1421, 1721, 1899, 2014 Aldafil 744 AM-2201 2008 aldicarb 61 Amanita 87, 1071, 1202, 1474, 1950 Aldifen 710 amanitin 87 Aldoclor 1371 amantadine 88 Aldomet 1371 Amaryl 994, 1311 Aldoril 1371 Amatine 1435 aldrin 63 amatoxin 87 alendronate 64 Ambien 2295 alendronic acid 64 AmBisome 127 Alerion 550 ambrisentan 90 Alesion 788 Ambrosan 91 Aleve 1497 ambroxol 91, 279 Alfacide 1608 Ambush 1671 Alfenta 65 Amcill 129 alfentanil 65 Amerge 1499 Alfospas 2118 Americaine 227 Alfusin 67 amethocaine 2056 alfuzosin 67 amethopterin 1343 Alganex 2044 ametryn 92 alimemazine 2184 amfepramone 671 Alimta 1642 amfetamine 124 aliskiren 68 Amias 342 alitretinoin 69 Amicar 98 alizapride 70 Amidate 851 alkaloids 34, 53, 134, 154, 184, 236, 293, 299, 335, 527, amidopyrine 103 531, 536, 580, 771, 802, 967, 978, 992, 1024, 1026, Amidrin 2274 1043, 1046, 1067, 1070, 1231, 1234, 1302, 1354, 1388, amifostine 93 1452, 1467, 1521, 1558, 1574, 1609, 1626, 1725, 1854, amikacin 94 1856, 1874, 1929, 1930, 1962, 1977, 2026, 2069, 2073, Amikin 94 2079, 2080, 2081, 2146, 2201, 2235, 2242, 2243, 2245, amiloride 96 2275 amineptine 97 Alka-Seltzer 750 amino acids 98, 157, 172, 545, 1005, 1063, 1583, 2024, Alkeran 1274 2079, 2200 alkylating agents 214, 312, 375, 420, 566, 584, 842, 1080, 1-aminoadamantane 88 1259, 1274, 1790, 2093, 2195 p-aminoaniline 1705 Allegra 890 aminocaproic acid 98, 346 Allerest 1494 aminoglutethimide 99 Allergen 147 aminoglycosides 94, 153, 984, 1137, 1506, 1636, 1974, 2122 allethrin 71 aminophenazone 103 Alleviate 71 p-aminophenol 142, 1542, 1679 Alli 1581 2-amino-1-phenylbutane 2312 Alloferin 60 aminophylline 2081 Allopur 72 5-(2-aminopropyl)benzofuran 2306, 2317 allopurinol 72 6-(2-aminopropyl)benzofuran 100 all-trans-retinoic acid 69, 2159 5-(2-aminopropyl)indole 101 allylbarbital 316 4-aminopyridine 102 allylbarbitone 316 aminopyrine 103 allyl trichloride 2172 aminorex 105, 1174 Almogran 74 p-aminosalicylic acid 106, 200 almonds 131, 554 5-aminosalicylic acid 200, 1301, 1993 Almotrex 74 aminosultopride 109 almotriptan 74 aminotriazole 115 Index 2321 amiodarone 107 Anethaine 2056 amisulpride 109 Anexate 905, 1265 Amitiza 1228 Anexsia 1050 amitraz 111 Angeliq 754 amitriptyline 112 Anginal 722 amitrole 115 angiotensin-converting enzyme inhibitors (see ACE inhibitors) Amizol 115 anidulafungin 140 Amloc 116 anileridine 141 amlodipine 116 aniline 142, 1542, 1679 Ammo 573 animal poisons 299, 344, 473, 861, 1354, 1929, 2073 ammonium bromide 281 anions 187, 271, 536, 872, 874, 1469, 1536, 1635 ammonium molybdate 1462 aniracetam 143 ammonium vanadyl tartrate 2222 anorectic agents (see appetite suppressants) amobarbital 118 Anoro Ellipta 2210, 2238 amodiaquine 120 Anorex 671 amoxapine 121, 1225 Ansaid 931 amoxicillin 123 Antabuse 728 Amoxil 123 antacids 83, 1239, 1551, 1574, 1625, 1760, 1859, 1867 amoxycillin 123 Antagonil 1513, 2275 AMP2 1395 Antara 877 Ampamet 143 anthelmintic agents 2, 56, 367, 654, 669, 1135, 1173, 1255, amphetamine 124, 229, 500, 700, 866, 872, 881, 1204, 1421, 1771, 1835, 2057, 2112, 2173 1265, 1305, 1319, 1779 Anthex 1255 l-amphetamine 1322, 1934 anti-aging drugs 552, 702, 1877 Amphotec 127 anti-alcoholism drugs 5, 143, 145, 338, 427, 728, 1070, 1144, amphotericin B 127 1601, 1628, 1740, 1841 ampicillin 129 anti-alopecia drugs 759, 892, 1443 Ampicin 129 anti-anginal drugs (see also vasodilators) 107, 133, 409, amprenavir 130, 949 685, 722, 1125, 1126, 1129, 1133, 1480, 1525, 1667, Ampyra 102 1779, 1868, 2111, 2185, 2234, 2316 amrinone 1091 anti-anxiety agents (see also benzodiazepines) 77, 275, Amrix 559 282, 310, 370, 373, 416, 1289, 2069, 2079, 2215 AMT 1413 anti-arrhythmic agents 46, 53, 107, 236, 304, 470, 677, 679, amudane 1013 685, 726, 752, 895, 1076, 1110, 1191, 1370, 1425, 1525, amygdalin 131 1602, 1726, 1762, 1787, 1801, 1817, 1854, 1966, 2124, amyl nitrite 133, 1539 2183, 2234 amylobarbitone 118 anti-arthritis agents (see also antirheumatic agents, COX-2 Amytal 118 inhibitors, narcotic analgesics, NSAIDs) 44, 150, 189, anabasine 134 1060 Anabol 1492 anti-asthma drugs (see bronchodilators, corticosteroids, anabolic steroids 137, 139, 262, 590, 610, 923, 987, 1308, leukotriene inhibitors) 1324, 1335, 1411, 1492, 1553, 1593, 1611, 1970, 2052, antibiotics (see also antifungal drugs, anti-leprosy drugs, 2157 antiseptics, antiviral agents, parasiticides) 41, 94, 123, anabolicum 2315 127, 129, 153, 180, 196, 197, 236, 247, 379, 388, 390, Anadrol 1611 391, 392, 393, 395, 395, 396, 397, 398, 399, 401, 402, Anafranil 505 403, 404, 405, 406, 410, 411, 421, 479, 490, 492, 497, Analeptin 2006 517, 538, 568, 588, 597, 601, 617, 662, 740, 747, 749, Analginum 723 791, 805, 806, 828, 891, 900, 951, 959, 974, 976, 982, Anagregal 2105 984, 1013, 1038, 1087, 1135, 1137, 1182, 1199, 1211, anagrelide 135 1299, 1422, 1427, 1441, 1471, 1482, 1485, 1506, 1544, Analeptin 2006 1555, 1559, 1564, 1580, 1582, 1589, 1615, 1636, 1641, Anamycin 806 1646, 1647, 1727, 1736, 1756, 1828, 1884, 1885, 1887, Anandron 1530 1888, 1914, 1951, 1956, 1974, 1987, 1989, 1991, 1992, Anaprox 1497 2015, 2027, 2028, 2031, 2033, 3034, 2039, 2060, 2104, AnaSed 2270 2106, 2110, 2122, 2187, 2199, 2224 anasterone 1611 antibodies 44, 208, 211, 242, 415, 1098 anastrozole 136 anti-cancer drugs (see antineoplastic agents) Anavar 1593 anticholinergic agents (see also antispasmodic drugs) 184, Anbesol 1693 251, 575, 665, 1006, 1067, 1110, 1565, 1584, 1793, Ancef 391 1806, 2116, 2182, 2196, 2198 Ancobon 902 anticoagulants 9, 29, 148, 273, 274, 442, 544, 582, 589, 664, Ancotil 902 674, 675, 715, 762, 782, 899, 1028, 1481, 1698, 1732, Andriol 2052 1898, 2117, 2266 Andro 2052 anticonvulsants 271, 281, 352, 433, 498, 507, 641, 829, 831, Androderm 2052 869, 906, 953, 961, 962, 1153, 1175, 1284, 1285, 1331, Androgel 2052 1359, 1432, 1598, 1664, 1691, 1709, 1776, 1783, 1878, androgen receptor antagonists 248, 576, 784, 933, 1530 1915, 1972, 2098, 2139, 2237, 2298 Android 1411 antidepressants 51, 97, 112, 121, 170, 176, 258, 307, 325, androstanediol 2053 485, 505, 621, 626, 741, 745, 757, 808, 852, 872, 898, androstenedione 137, 610, 1778 920, 937, 1088, 1138, 1184, 1206, 1209, 1250, 1270, androstenetrione 139 1305, 1403, 1438, 1447, 1456, 1503, 1556, 1578, 1637, androsterone 611, 2053 1683, 1797, 1826, 1870, 1942, 1946, 1973, 2099, 2153, Androxy 923 2155, 2189, 2231, 2239, 2241, 2263, 2308 Anectine 1982 antidiabetic agents (see hypoglycemic
Recommended publications
  • Sectionpm E] Analytical Кгейг“' Control Radiopharmaceuticals

    Sectionpm E] Analytical Кгейг“' Control Radiopharmaceuticals

    section P m e ] Analytical кгейг“' Control i - ¡ Q f Radiopharmaceuticals Proceedings of a Panel Vienna, • ° 7-11 July 1969 INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, 1970 ANALYTICAL CONTROL OF RADIOPHARMACEUTICALS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GREECE .NORWAY ALBANIA GUATEMALA PAKISTAN ALGERIA HAITI PANAMA ARGENTINA HOLY SEE PÂRAGUAY AUSTRALIA HUNGARY PERU AUSTRIA ICELAND PHILIPPINES BELGIUM INDIA POLAND BOLIVIA INDONESIA PORTUGAL BRAZIL IRAN ROMANIA BULGARIA IRAQ' SAUDI ARABIA BURMA IRELAND SENEGAL BYELORUSSIAN SOVIET ISRAEL SIERRA LEONE SOCIALIST REPUBLIC ITALY SINGAPORE CAMBODIA IVORY COAST SOUTH AFRICA CAMEROON JAMAICA SPAIN CANADA JAPAN SUDAN CEYLON JORDAN SWEDEN CHILE KENYA SWITZERLAND CHINA KOREA, REPUBLIC OF SYRIAN ARAB REPUBLIC COLOMBIA KUWAIT THAILAND CONGO, DEMOCRATIC LEBANON TUNISIA REPUBLIC OF LIBERIA TURKEY COSTA RICA LIBYAN ARAB REPUBliC UGANDA CUBA LIECHTENSTEIN UKRAINIAN'SOVIET SOCIALIST CYPRUS LUXEMBOURG REPUBLIC CZECHOSLOVAK SOCIALIST MADAGASCAR UNION OF SOVIET SOCIALIST REPUBLIC MALAYSIA REPUBLICS DENMARK MALI UNITED ARAB REPUBLIC DOMINICAN REPUBLIC MEXICO UNITED KINGDOM OF GREAT ECUADOR MONACO BRITAIN AND NORTHERN EL SALVADOR MOROCCO IRELAND ETHIOPIA NETHERLANDS UNITED STATES OF AMERICA FINLAND NEW ZEALAND URUGUAY FRANCE NICARAGUA VENEZUELA GABON NIGER VIET-NAM GERMANY, FEDERAL REPUBLIC OF NIGERIA YUGOSLAVIA GHANA *• ZAMBIA The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters,
  • Minnesota Statutes 1979 Supplement

    Minnesota Statutes 1979 Supplement

    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
  • A Review of Synthetic Fentanyl Metabolism and the Metabolism of Select Synthetic Fentanyl Analogues

    A Review of Synthetic Fentanyl Metabolism and the Metabolism of Select Synthetic Fentanyl Analogues

    A review of synthetic fentanyl metabolism and the metabolism of select synthetic fentanyl analogues Gerard Lee A thesis submitted for the completion of a degree in Master of Forensic Science (Professional Practice) in The School of Veterinary and Life Sciences Murdoch University Supervisors: Associate Professor James Speers (Murdoch) Associate Professor Bob Mead (Murdoch) Semester 1, 2019 i Declaration I declare that this thesis does not contain any material submitted previously for the award of any other degree or diploma at any university or other tertiary institution. Furthermore, to the best of my knowledge, it does not contain any material previously published or written by another individual, except where due reference has been made in the text. Finally, I declare that all reported experimentations performed in this research were carried out by myself, except that any contribution by others, with whom I have worked is explicitly acknowledged. ii Acknowledgements I would like to thank my supervisor Bob Mead for his time guiding me and providing feedback on this endeavour. He has been a great help providing insights and advice from when I started university at Murdoch until now for which I am extremely grateful. To James Speers, thank you for helping me find a direction for this project when I started out. And finally, to my family and friends for their encouragement and support. iii Table of Contents Title page. ...............................................................................................................................I
  • 18 December 2020 – to Date)

    18 December 2020 – to Date)

    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition

    Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition

    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Enhancement of Dissolution and Oral Bioavailability of Gliquidone with Hydroxy Propyl-Β-Cyclodextrin

    Enhancement of Dissolution and Oral Bioavailability of Gliquidone with Hydroxy Propyl-Β-Cyclodextrin

    ORIGINAL ARTICLES Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad, India Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-b-cyclodextrin S. Sridevi, A. S. Chauhan, K. B. Chalasani, A. K. Jain, P. V. Diwan Received November 15, 2002, accepted May 5, 2003 Dr. Prakash V. Diwan, Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad – 500 007 A.P., India [email protected] Pharmazie 58: 807–810 (2003) The virtual insolubility of gliquidone in water results in poor wettability and dissolution characteristics, which may lead to a variation in bioavailability. To improve these characteristics of gliquidone, binary systems with hydroxypropyl-b-cyclodextrin (HP-b-CD) were prepared by classical methods such as physical mixing, kneading, co-evaporation and co-lyophilization. The solid state interaction between the drug and HP-b-CD was assessed by evaluating the binary systems with X-ray diffraction, differen- tial scanning calorimetry and IR- spectroscopy. The results establish the molecular encapsulation and amorphization of gliquidone. The phase solubility profile of gliquidone in aqueous HP-b-CD vehicle À1 resulted in an AL type curve with a stability constant of 1625 M . The dissolution rate of binary sys- tems was greater than that of pure drug and was significantly higher in the case of co-lyophilized and co-evaporated systems. Upon oral administration, [AUC]0-a was significantly higher in case of co-lyo- philized (2 times) and co-evaporated systems (1.5 times) compared to pure drug suspension while other binary systems showed only a marginal improvement. The study ascertained the utility of HP-b- CD in enhancing the oral bioavailability of gliquidone, and points towards a strong influence of the preparation method on the physicochemical properties.
  • Systematic Review of the Effect of Intravenous Lipid Emulsion Therapy for Non-Local Anesthetics Toxicity

    Systematic Review of the Effect of Intravenous Lipid Emulsion Therapy for Non-Local Anesthetics Toxicity

    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 Systematic review of the effect of intravenous lipid emulsion therapy for non-local anesthetics toxicity Michael Levine, Robert S. Hoffman, Valéry Lavergne, Christine M. Stork, Andis Graudins, Ryan Chuang, Samuel J. Stellpflug, Martin Morris, Andrea Miller-Nesbitt, Sophie Gosselin & for the Lipid Emulsion Workgroup* To cite this article: Michael Levine, Robert S. Hoffman, Valéry Lavergne, Christine M. Stork, Andis Graudins, Ryan Chuang, Samuel J. Stellpflug, Martin Morris, Andrea Miller-Nesbitt, Sophie Gosselin & for the Lipid Emulsion Workgroup* (2016) Systematic review of the effect of intravenous lipid emulsion therapy for non-local anesthetics toxicity, Clinical Toxicology, 54:3, 194-221, DOI: 10.3109/15563650.2015.1126286 To link to this article: http://dx.doi.org/10.3109/15563650.2015.1126286 Published online: 06 Feb 2016. Submit your article to this journal Article views: 692 View related articles View Crossmark data Citing articles: 2 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 Download by: [UPSTATE Medical University Health Sciences Library] Date: 03 August 2016, At: 08:19 CLINICAL TOXICOLOGY, 2016 VOL. 54, NO. 3, 194–221 http://dx.doi.org/10.3109/15563650.2015.1126286 REVIEW Systematic review of the effect of intravenous lipid emulsion therapy for non-local anesthetics toxicity Michael Levinea, Robert S. Hoffmanb, Vale´ry Lavergnec, Christine M. Storkd, Andis Graudinse, Ryan Chuangf, Samuel J. Stellpflugg, Martin Morrish, Andrea Miller-Nesbitth, Sophie Gosselini and for the Lipid Emulsion Workgroup* aDepartment of Emergency Medicine, Section of Medical Toxicology, University of Southern California, Los Angeles, CA, USA; bDivision of Medical Toxicology, Ronald O.
  • Sulfonylurea Review

    Sulfonylurea Review

    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
  • Changing Pattern of Epidemic Dropsy in North India

    Changing Pattern of Epidemic Dropsy in North India

    Epidemic Dropsy in North India N. Sharma et al. ORIGINAL ARTICLE Changing Pattern of Epidemic Dropsy in North India NAVNEET SHARMA1,*, NAINA MOHAN 2, ASHISH BHALLA1, AMAN SHARMA1, SURJIT SINGH 1 1 The Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India 2 King's College London, Strand, London, United Kingdom Abstract Background: Epidemic dropsy occurs due to ingestion of mustard oil contaminated with oil from Argemone mexicana, leading to edema and tenderness of the abdomen, upper and lower limbs. In this study, clinical profiles of patients presented with epidemic dropsy in north India are described. Methods: This was a prospective study of patients presented with epidemic dropsy to the emergency department of Nehru Hospital, during the period from March 2004 to December 2011. Inclusion criteria were patients presenting with tender bilateral pitting leg edema and dermal telangiectasia. Clinical and laboratory data of patients were entered into case record forms at the time of presentation until discharge from the hospital. Results: Leg edema was the principal symptom in our series, and was in concurrence with current literature. Erythema has only been reported in 35-82% of published series, though it was present in all of our patients. Similarly, features such as diarrhea, hepatomegaly and anemia were more frequent in our cases compared to the literature. Furthermore, pancytopenia which was documented on peripheral blood counts in 54% of our cases has never been reported before. Conclusion: Epidemic dropsy should be considered in patients presenting with progressive erythema, edema, and tenderness of the limbs who had a history of consumption of mustard oil and confirmation of Argemone oil contamination according to laboratory tests.
  • Disposition of T Oxic Drugs and Chemicals

    Disposition of T Oxic Drugs and Chemicals

    Disposition of Toxic Drugs and Chemicals in Man, Eleventh Edition Eleventh Edition in Man and Chemicals Drugs Toxic Disposition of The purpose of this work is to present in a single convenient source the current essential information on the disposition of the chemi- cals and drugs most frequently encountered in episodes of human poisoning. The data included relate to the body fluid concentrations of substances in normal or therapeutic situations, concentrations in fluids and tissues in instances of toxicity and the known metabolic fate of these substances in man. Brief mention is made of specific analytical procedures that are applicable to the determination of each substance and its active metabolites in biological specimens. It is expected that such information will be of particular interest and use to toxicologists, pharmacologists, clinical chemists and clinicians who have need either to conduct an analytical search for these materials in specimens of human origin or to interpret 30 Amberwood Parkway analytical data resulting from such a search. Ashland, OH 44805 by Randall C. Baselt, Ph.D. Former Director, Chemical Toxicology Institute Bookmasters Foster City, California HARD BOUND, 7” x 10”, 2500 pp., 2017 ISBN 978-0-692-77499-1 USA Reviewer Comments on the Tenth Edition “...equally useful for clinical scientists and poison information centers and others engaged in practice and research involving drugs.” Y. Caplan, J. Anal. Tox. “...continues to be an invaluable and essential resource for the forensic toxicologist and pathologist.” D. Fuller, SOFT ToxTalk “...has become an essential reference book in many laboratories that deal with clinical or forensic cases of poisoning.” M.